ARA-290

Potential Benefits of ARA-290 Peptide

• Neuropathic Symptom Relief: Research suggests ARA 290 has shown promising results in alleviating neuropathic symptoms in patients with type 2 diabetes and sarcoidosis. Both intravenous and subcutaneous administration of this treatment have demonstrated its versatility as a therapeutic agent. [1] [2].
• Metabolic Control: Besides neuropathic symptom relief, ARA 290 also exhibits promising effects on metabolic control in subjects with type 2 diabetes [1]. This dual-action nature may make it an attractive therapeutic option for managing complex, co-morbid conditions.
• Increase in Corneal Nerve Fiber Density: A study demonstrated that ARA 290 can increase corneal nerve fiber density in patients with sarcoidosis-associated small nerve fiber loss [3]. This suggests that ARA 290 has regenerative properties, possibly due to its action on the innate repair receptor.
• Chronic Neuropathic Pain Treatment: ARA 290 acts at the innate repair receptor, a heteromer of the erythropoietin receptor and β-common receptor. This mechanism of action has been associated with the alleviation of chronic neuropathic pain in sarcoidosis patients [4].
• Promising SPECT Tracer for Cardiac Ischemia: ARA-290 peptide has been evaluated for its potential as a Single Photon Emission Computed Tomography (SPECT) tracer for targeting cardiac ischemic regions. The results suggest potential diagnostic benefits [5].
• Treatment of Painful Diabetic Neuropathy: Clinical trials have shown the safety and efficacy of ARA 290 in treating painful diabetic neuropathy [6]. Further larger clinical trials are needed for more conclusive results.
• Potential Neuroprotective Benefits: Apart from its analgesic properties, ARA 290 also appears to have neuroprotective benefits, making it a potential treatment for post-stroke depression [6].
• Attenuating Apoptosis and Inflammation: ARA 290 has been studied for its role in attenuating apoptosis and inflammation in critical limb ischemia, suggesting its potential use in vascular diseases [7] [8].
• Protection against Cytokine-Induced Apoptosis: Research has indicated that ARA 290 can protect rat islets from cytokine-induced apoptosis [8], suggesting possible applications in autoimmune conditions.
• Reducing Tissue Damage: Studies imply that ARA-290 peptide may reduce tissue damage by reducing inflammation [9].

References

[1] https://pubmed.ncbi.nlm.nih.gov/25387363/

[2] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3563705/

[3] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3883966/

[4] https://www.tandfonline.com/doi/ full/10.1517/21678707.2013.719289

[5] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC8917853/

[6] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4365069/

[7] https://www.sciencedirect.com/science/ article/pii/S074152141301238X

[8] https://www.researchgate.net/ publication/310146980

[9] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5741312/

DISCLAIMER: We do not supply peptides to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. Our team of dedicated professionals are committed to providing an extensive range of products used ONLY in the process of laboratory research by responsible trained and professional individuals. All products listed on this website (https://estonia.direct-peptides.com) and provided through Direct Peptides are intended for laboratory research purposes only. The products listed on this website are NOT for human or animal consumption or ingestion of any kind.